WHO Sounds Alert Over Severe Lack of Obesity Medications

Less than one in 10 individuals who could benefit from GLP-1 drugs including Wegovy are able to get them, states the World Health Organization as it publishes its inaugural recommendations on the drugs.

With over a billion people worldwide currently obese, it is urging increased and just availability to GLP-1 medication.

Per projections, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.

"The latest guidance recognises that excess weight is a long-term condition that can be addressed with comprehensive and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.

Significant expense, limited production capacity, and distribution challenges are significant obstacles to broad availability to the injections that can aid individuals in losing significant body mass, says the body.

GLP-1 Therapy Scarcity

Despite the current best projected outlook, the production of GLP-1 therapies could only cover around 100 million people – fewer than 10% of the global need, per the WHO.

The recommendation encourages nations and manufacturers to increase access, by measures like licensing agreements.

A patent on semaglutide – the core ingredient of the drug Wegovy – is set to lapse in a number of countries in 2026.

The Way Weight-Loss Jabs Operate

These medications mimick a biological compound to slow digestion, reduce hunger and enhance feelings of fullness so users consume fewer calories.

People usually see weight reduction after several weeks of starting on the regular doses.

Studies points to people may regain a significant portion within a year of stopping the medication, when their usual appetite resume.

Being carrying excess weight elevates your likelihood for contracting health problems, such as diabetes, heart disease, brain attack, and some cancers.

Obesity impacts people in all nations and was responsible for over three and a half million fatalities worldwide in 2024, according to the health agency.